These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38710951)

  • 1. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
    Rodón J; Damian S; Furqan M; García-Donas J; Imai H; Italiano A; Spanggaard I; Ueno M; Yokota T; Veronese ML; Oliveira N; Li X; Gilmartin A; Schaffer M; Goyal L
    Nat Med; 2024 Jun; 30(6):1645-1654. PubMed ID: 38710951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of Erdafitinib in Patients With Tumors With
    Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With
    Sweis RF; Gajate P; Morales-Barrera R; Lee JL; Necchi A; de Braud F; Penel N; Grünwald V; Maruzzo M; Meran J; Ishida TC; Bao W; Zhou Y; Ellinghaus P; Rosenberg JE
    JAMA Oncol; 2024 Nov; 10(11):1565-1570. PubMed ID: 39298147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of chemo- and radiotherapy treatments on selfish de novo FGFR2 mutations in sperm of cancer survivors.
    Maher GJ; Bernkopf M; Koelling N; Wilkie AOM; Meistrich ML; Goriely A
    Hum Reprod; 2019 Aug; 34(8):1404-1415. PubMed ID: 31348830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
    Hamilton EP; Falchook GS; Wang JS; Fu S; Oza AM; Imedio ER; Kumar S; Ottesen L; Mugundu GM; de Bruin EC; O'Connor MJ; Jones SF; Spigel DR; Li BT
    Target Oncol; 2024 Nov; 19(6):879-892. PubMed ID: 39487373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
    Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2024 Apr; 8():e2300407. PubMed ID: 38603650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with
    George S; Blay JY; Chi P; Jones RL; Serrano C; Somaiah N; Gelderblom H; Zalcberg JR; Reichmann W; Sprott K; Cox P; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S
    Future Oncol; 2024; 20(27):1973-1982. PubMed ID: 39229786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
    Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H
    Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
    Maruyama D; Jacobsen E; Porcu P; Allen P; Ishitsuka K; Kusumoto S; Narita T; Tobinai K; Foss F; Tsukasaki K; Feldman T; Imaizumi Y; Izutsu K; Morishima S; Yamauchi N; Yuda J; Brammer JE; Kawamata T; Ruan J; Nosaka K; Utsunomiya A; Wang J; Zain J; Kakurai Y; Yamauchi H; Hizukuri Y; Biserna N; Tachibana M; Inoue A; Horwitz SM
    Lancet Oncol; 2024 Dec; 25(12):1589-1601. PubMed ID: 39486432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
    Miller S; Jiang R; Schipper M; Fritsche LG; Strohbehn G; Wallace B; Brinzevich D; Falvello V; McMahon BH; Zamora-Resendiz R; Ramnath N; Dai X; Sankar K; Edwards DM; Allen SG; Yoo S; Crivelli S; Green MD; Bryant AK
    Lancet Oncol; 2024 Dec; 25(12):1666-1676. PubMed ID: 39551068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for supporting pregnant women's decision-making about mode of birth after a caesarean.
    Horey D; Kealy M; Davey MA; Small R; Crowther CA
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD010041. PubMed ID: 23897547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.